The Science Of CRISPR/Cas9

Emily BurkeBiologics, Business of Biotech, Cancer, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Development, Drug Targets, Genetics, Genomics, Mechanism of Action, Ribonucleic Acid (RNA)

CRISPR/CAS9 UPDATE As CRISPR/Cas9 adds new indications to its resume, legal battles over its IP continue to be waged in the US and Europe. On the clinical front, CRISPR/Cas9 entered its first human trial at Sichuan University (Chengdu, China) last fall for metastatic lung cancer, and is widely expected to do so in the U.S. by the end of the year. This … Read More

The Science Of CRISPR/CAS9

Emily BurkeBiologics, Business of Biotech, Cancer, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Development, Drug Targets, Genomics, Mechanism of Action, Ribonucleic Acid (RNA), The WEEKLY

 CRISPR/CAS9 UPDATE CRISPR/Cas9 can’t seem to stay out of the news — from first in human to patent disputes, we here at the WEEKLY want to update you on this hot technology. A group of scientists from the State Key Laboratory of Proteomics (Beijing, China) and the National Center for Protein Sciences (Beijing, China) recently reported the first ever edit using CRISPR/Cas9 in healthy human … Read More

A Drop Of Gene Therapy

Emily BurkeBiologics, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Development, Drug Targets, Genetics, Mechanism of Action, Orphan Disease, Orphan Drugs, The WEEKLY

A Walk In The Park For Hemophilia? Imagine tripping over your feet during a leisurely stroll down the sidewalk. Ouch! Your knees are scraped below your shorts and blood starts to drip. A quick wipe from a conveniently pocketed napkin and soon enough, you are the proud owner of some new scabs. Life goes on. If you are one of … Read More

Next-Generation CAR-T

Emily BurkeBiologics, Business of Biotech, Cancer, Clinical Trials, Drug Development, Drug Targets, Genomics, Mechanism of Action, Monoclonal Antibodies, The WEEKLY

The Race Is On Our last WEEKLY—Hacking the Immune Response—unveiled the science behind CAR-T and TCR, two immunotherapies under the microscope of the mainstream press. The well-deserved media attention highlights the ability of these “living drugs” to recognize and obliterate cancers. With all of the early phase clinical success, a few challenges have popped up: • Safety: CAR-T and TCR can … Read More

A Drop Of Biotech

Emily BurkeCancer, Clinical Trials, Cocktail Fodder, Diagnostics, Drug Development, Genomics, HIV, Orphan Disease, Orphan Drugs, The WEEKLY

Basics of Blood Disorders Blood is the carrier of a multitude of fundamental body processes—responsible for delivering vital nutrients/oxygen and for removing wastes. Like the highway exchange feeding a city of life, blood is simply essential. The branch of medicine concerned with the study, diagnosis, treatment, and prevention of blood related diseases is known as hematology. This single therapeutic area covers a broad range … Read More

It’s A Great Time To Be In Biotech

Emily BurkeBiologics, Biotech Basics, Cancer, Clinical Trials, Drug Approvals, Drug Development, Drug Targets, FDA, Genomics, HIV, Mechanism of Action, Monoclonal Antibodies, The WEEKLY

It’s a great time to be in biotech—new therapeutics are breaking ground faster than we can say “monoclonal antibody” and the technologies behind them are heavy with promise and potential. Our mission is to keep your industry knowledge up to date and the WEEKLY is here to give you a smart primer on the basics. Below we have outlined several … Read More

Designer Genes: An Introduction To Genome-Editing

Emily BurkeBiologics, Biotech Basics, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Targets, Genetics, Genomics, HIV, Mechanism of Action, Ribonucleic Acid (RNA), The WEEKLY

Five years ago, altering an individual’s genome would have been labeled unimaginable. Fast forward to today and one of the hottest new developments in biotech is genome-editing—the ability to selectively disable or edit the sequence of specific genes. In this WEEKLY we will compare and contrast the different genome-editing platforms in development and discover how close we are to a clinical reality. Got Gaps in Your … Read More

Science Geeks Rock!

Emily BurkeThe WEEKLY

THE SCIENCE DRIVING BIOTECH Next week, BioTech Primer will be participating the BIO 2014 Annual International Convention in San Diego, CA. The event draws thousands and, as in years past, BioTech Primer will be headlining a few events. Join us and learn! On Monday, June 23, I will be teaching an all-day class called “The Science Driving Biotech.” What can … Read More

Genome Editing: Curing HIV?

Emily BurkeGenetics, Genomics, The WEEKLY

CURING HIV? HIV destroys its victim’s immune system by infecting T-cells, a type of white blood cell critical for immunity. HIV binds to two different proteins on the T-cell’s surface: CD4 and CCR5. In the late 1990s, scientists identified a population of individuals seemingly resistant to HIV infection. Despite multiple known exposures, they did not get infected. It turned out … Read More